Patients with hypertension and chronic kidney disease as a priority group for primary prevention programs
E. A. Medvedeva,
E. I. Usova,
A. E. Solovyova,
M. V. Dubinina,
S. V. Villevalde,
N. E. Zvartau,
E. V. Shlyakhto https://doi.org/10.15829/1560-4071-2024-5812
EDN: LMYMWP
Abstract
The combination of hypertension and chronic kidney disease is a stage of the cardiovascular-renal-metabolic continuum and associated with adverse cardiovascular and renal outcomes. Epidemiological aspects, accessible screening algorithm within outpatient monitoring, availability of modern cardiac and renal protective strategies make it possible to select this high-risk group as a priority for the implementation of effective targeted primary prevention and maintaining the trend of reducing cardiovascular morbidity and mortality in the medium- and long-term.
About the Authors
E. A. Medvedeva
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
E. I. Usova
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
A. E. Solovyova
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
M. V. Dubinina
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
S. V. Villevalde
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
N. E. Zvartau
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
E. V. Shlyakhto
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
References
1. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982-2004. doi:10.1161/CIR.0000000000001191.
2. Jonsson AJ, Lund SH, Eriksen BO, et al. The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds. Kidney Int. 2020;98(5):1286-95. doi:10.1016/j.kint.2020.06.017.
3. Kobalava ZhD, Villevalde SV, Agmanova NKh, et al. The prevalence of chronic kidney disease markers in arterial hypertension patients and relation with diabetes: results of epidemiological study khronograph. Russian Journal of Cardiology. 2018;(2):91-101. (In Russ.) doi:10.15829/1560-4071-2018-2-91-101.
4. Oschepkova EV, Aksenova AV, Orlovsky AА, Chazova IE. Chronic kidney disease in outpatients with arterial hypertension: clinical characteristics and treatment efficacy (according to the national registry). Terapevticheskii Arkhiv. 2022;94(7):810-5. (In Russ.) doi:10.26442/00403660.2022.07.201744.
5. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305. doi:10.1056/NEJMoa041031.
7. Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82. (In Russ.) Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013;3:1-150.
9. Kofod DH, Carlson N, Ballegaard EF, et al. Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2023;22(1):140. doi:10.1186/s12933-023-01867-8.
10. Eknoyan G. Chronic kidney disease definition and classification: no need for a rush to judgment. Kidney Int. 2009;75(10):1015-8. doi:10.1038/ki.2009.53.
11. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.
12. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. doi:10.1016/S0140-6736(15)01225-8.
13. Jermendy G, Ruggenenti P. Preventing microalbuminuria in patients with type 2 diabetes. Diabetes Metab Res Rev. 2007;23(2):100-10. doi:10.1002/dmrr.693.
14. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50(5):1641-50. doi:10.1038/ki.1996.480.
15. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26-39. doi:10.1016/j.kint.2017.12.027.
16. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi:10.1056/NEJMoa2024816.
17. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. doi:10.1016/S2213-8587(20)30369-7.
18. Waijer SW, Vart P, Cherney DZI, et al. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 2022;65(7):1085-97. doi:10.1007/s00125-022-05694-6.
19. Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-27. doi:10.1056/NEJMoa2204233.
20. EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):51-60. doi:10.1016/S2213-8587(23)00322-4.
Supplementary files
- Patients with hypertension and chronic kidney disease represent a priority group for the implementation of primary prevention measures due to the high risk of adverse cardiovascular and renal outcomes.
- Such patients can be considered as a potential group for the implementation of regional and/or federal medicine assistance programs.
Review
For citations:
Medvedeva E.A., Usova E.I., Solovyova A.E., Dubinina M.V., Villevalde S.V., Zvartau N.E., Shlyakhto E.V. Patients with hypertension and chronic kidney disease as a priority group for primary prevention programs. Russian Journal of Cardiology. 2024;29(3):5812. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5812. EDN: LMYMWP
Views:
1456
Email this article 